Abstract
Since Warburg proposed in 1956 that cancer cells exhibit increased glycolysis due to mitochondrial damage, numerous researchers have assumed that glycolysis is the predominant ATP supplier for cancer cell energy-dependent processes. However, chemotherapeutic strategies using glycolytic inhibitors have been unsuccessful in arresting tumor proliferation indicating that the Warburg hypothesis may not be applicable to all existing neoplasias. This review analyzes recent information on mitochondrial metabolism in several malignant neoplasias emphasizing that, although tumor cells maintain a high glycolytic rate, the principal ATP production may derive from active oxidative phosphorylation. Thus, anti-mitochondrial drug therapy may be an adequate adjuvant strategy to arrest proliferation of oxidative phosphorylation-dependent neoplasias.
Keywords: Anti-mitochondrial drugs, glycolysis, oxidative phosphorylation, Warburg hypothesis, multi-site therapy, multi-drug therapy, respiratory inhibitors, uncouplers, lipophilic cation drugs, mitochondrial substrate oxidation, Krebs cycle
Current Medicinal Chemistry
Title: Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Volume: 18 Issue: 21
Author(s): Sara Rodriguez-Enriquez, Juan Carlos Gallardo-Perez, Alvaro Marin-Hernandez, Jose Luis Aguilar-Ponce, Edna Ayerim Mandujano-Tinoco, Abelardo Meneses and Rafael Moreno-Sanchez
Affiliation:
Keywords: Anti-mitochondrial drugs, glycolysis, oxidative phosphorylation, Warburg hypothesis, multi-site therapy, multi-drug therapy, respiratory inhibitors, uncouplers, lipophilic cation drugs, mitochondrial substrate oxidation, Krebs cycle
Abstract: Since Warburg proposed in 1956 that cancer cells exhibit increased glycolysis due to mitochondrial damage, numerous researchers have assumed that glycolysis is the predominant ATP supplier for cancer cell energy-dependent processes. However, chemotherapeutic strategies using glycolytic inhibitors have been unsuccessful in arresting tumor proliferation indicating that the Warburg hypothesis may not be applicable to all existing neoplasias. This review analyzes recent information on mitochondrial metabolism in several malignant neoplasias emphasizing that, although tumor cells maintain a high glycolytic rate, the principal ATP production may derive from active oxidative phosphorylation. Thus, anti-mitochondrial drug therapy may be an adequate adjuvant strategy to arrest proliferation of oxidative phosphorylation-dependent neoplasias.
Export Options
About this article
Cite this article as:
Rodriguez-Enriquez Sara, Carlos Gallardo-Perez Juan, Marin-Hernandez Alvaro, Luis Aguilar-Ponce Jose, Ayerim Mandujano-Tinoco Edna, Meneses Abelardo and Moreno-Sanchez Rafael, Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias, Current Medicinal Chemistry 2011; 18 (21) . https://dx.doi.org/10.2174/092986711796391561
DOI https://dx.doi.org/10.2174/092986711796391561 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Trends of Biocompatible and Biodegradable Nanoparticles in Drug Delivery: A Review
Current Medicinal Chemistry Bioactive Metabolites from Pathogenic and Endophytic Fungi of Forest Trees
Current Medicinal Chemistry A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Nose to Brain Delivery: New Trends in Amphiphile-Based “Soft” Nanocarriers
Current Pharmaceutical Design Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Use of Bimetallic Nanoparticles in the Synthesis of Heterocyclic Molecules
Current Organic Chemistry Pharmacological Targeting of the Hsp70 Chaperone
Current Topics in Medicinal Chemistry New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles
Current Drug Delivery Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis <i>In Vitro</i>
CNS & Neurological Disorders - Drug Targets Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Current Medicinal Chemistry CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery